Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot randomized study of rilpivirine-based antiretroviral therapy in virologically suppressed adults with HIV and metabolic liver disease
2022-503110-23-00Phase 4Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rilpivirine in metabolic liver disease and human immunodeficiency virus infection (HIV) (3 arms), sponsored by Fundación SEIMC-GeSIDA. Primary endpoints: Primary endpoint 1 and Primary endpoint 2. Started May 2023; status: completed.
02
Drugs
rilpivirine
03
Conditions
metabolic liver diseasehuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2022-503110-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503110-23-00.